Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, reported that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, allowing Edesa to expand recruitment to the United States.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.